Journal of Pharmaceutical Investigation

The Korean Society of Pharmaceutical Sciences and Technology (한국약제학회)
권호 표지
DOI QR코드

DOI QR Code

Pharmacokinetic Analysis of Levofloxacin in Healthy Korean Volunteers

  • Kim, Seung-Yong (Bioanalysis and Biotransformation Research Center, Korea Institute of Science and Technology) ;
  • Chung, Youn-Bok (National Research Laboratory of PK/PD, Biotechnology Research Institute, College of Pharmacy, Chungbuk National University) ;
  • Pyo, Hee-Soo (Bioanalysis and Biotransformation Research Center, Korea Institute of Science and Technology) ;
  • Kwon, Oh-Seung (Bioanalysis and Biotransformation Research Center, Korea Institute of Science and Technology)
  • Published : 2008.08.20
Download PDF
⟨ Previous Next ⟩

Abstract

A sensitive and simple method of determining the plasma levofloxacin (LFX, CAS 100986-85-4) concentrations in human volunteers by liquid-liquid extraction were developed and validated by using a high-performance liquid chromatography/diode array detector. The method was also applied to pharmacokinetic study of LFX. LFX was orally administered to 8 healthy male Korean volunteers at single lowest dose of 200 mg, compared to the published reports in which more than 500 mg of LFX was orally administered. LFX in human plasma was determined. The detection limit of LFX was $0.05\;{\mu}g/mL$. $C_{max}$ value was $2.48{\pm}0.67\;{\mu}g/mL$. $AUC_{0{\to}24\;hr$} and $AUC_{0{\to}{\infty}}$ were $14.52{\pm}3.35\;{\mu}g/mL$ and $16.00{\pm}3.66\;{\mu}g{\cdot}hr/mL$, respectively. The terminal half-life was $6.87{\pm}0.46\;hr$. Our pharmacokinetic parameters were very consistent with that previously reported, showing good correlation between LFX doses and AUC ($r^2=0.995$). This method can be useful for the pharmacokinetics and bioequivalence study with relatively low dose for reducing the main side effects of LFX.

Keywords

References

  1. S. Bottcher, H. von Baum, T. Hoppe-Tichy, C. Benz and H.G. Sonntag, An HPLC assay and a microbiological assay to determine levofloxacin in soft tissue, bone, bile and serum, J. Pharm. Biomed. Anal., 25(2), 197-203 (2001) https://doi.org/10.1016/S0731-7085(00)00478-7
  2. F.A.Wong, S.J. Juzwin and S.C. Flor, Rapid stereospecific high-performance liquid chromatographic determination of levofloxacin in human serum and urine, J. Pharm. Biomed. Anal., 15, 765-771 (1997) https://doi.org/10.1016/S0731-7085(96)01890-0
  3. K. Sato, Y. Matsuura, M. Inoue, T. Une, Y. Osada, H. Ogawa and S. Mitsuhashi, In vitro and in vivo activity of DL-8280, a new oxazine derivative, Antimicrob. Agents Chemother., 22, 548-553 (1982) https://doi.org/10.1128/AAC.22.4.548
  4. S. Djabarouti, E. Boselli, B. Allaouchiche, B. Ba, A.T. Nguyen, J.B. Gordien, J.M. Bernadou, M.C. Saux and D. Breilh, Determination of levofloxacin in serum, bronchoalveolar lavage and bone tissues by high-performance liquid chromatography with ultraviolet detection using a fully automated extraction method, J. Chromatogr. B., 799, 165-172 (2004) https://doi.org/10.1016/j.jchromb.2003.10.031
  5. H. Liang, M.B. Kays and K.M. Sowinski, Separation of levofloxacin, ciprofloxacin, gatifloxacin, moxifloxacin, trovafloxacin and cinoxacin by high-performance liquid chromatography: application to levofloxacin determination in human serum, J. Chromatogr. B, 772, 53-63 (2002) https://doi.org/10.1016/S1570-0232(02)00046-6
  6. T. Ohkubo, M. Kudo and K. Sugawara, Determination of ofloxacin in human serum by high-performance liquid chromatography with column switching, J. Chromatogr., 573, 289- 293 (1992) https://doi.org/10.1016/0378-4347(92)80131-9
  7. O. Okazaki, H. Aoki and H. Hakasui, High-performance liquid chromatographic determination of (S)-(-)-ofloxacin and its metabolites in serum and urine using a solid-phase clean-up, J. Chromatogr., 563, 313-322 (1991) https://doi.org/10.1016/0378-4347(91)80037-D
  8. J. Macek and P. Ptacek, Determination of ofloxacin in human serum using high-performance liquid chromatography and fluorescence detection, J. Chromatogr. B Biomed. Appl., 673(2), 316-319 (1995) https://doi.org/10.1016/0378-4347(95)00263-5
  9. E.M. Grant, M. Zhong, J.F. Fitzgerald, D.P. Nicolau, C. Nightingale and R. Quintiliani, Lack of interaction between levofloxacin and oxycodone: pharmacokinetics and drug disposition, J. Clin. Pharmacol., 41(2), 206-209 (2001) https://doi.org/10.1177/00912700122009890
  10. A. Lubasch, I. Keller, K. Borner, P. Koeppe and H. Lode, Comparative pharmacokinetics of ciprofloxacin, gatifloxacin, grepafloxacin, levofloxacin, trovafloxacin, and moxifloxacin after single oral administration in healthy volunteers, Antimicrob. Agents Chemother.,. 44(10), 2600-2603 (2000) https://doi.org/10.1128/AAC.44.10.2600-2603.2000
  11. S.C. Chien, F.A. Wong, C.L. Fowler, S.V. Callery-D'Amico, R.R. Williams, R. Nayak and A.T. Chow, Double-blind evaluation of the safety and pharmacokinetics of multiple oral once-daily 750-milligram and 1-gram doses of levofloxacin in healthy volunteers. Antimicrob, Agents. Chemother., 42(4), 885-888 (1998)
  12. M. Furlanut, L. Brollo, E. Lugatti, E. Di Qual, F. Dolcet, G. Talmassons and F. Pea, Pharamcokinetic aspects of levofloxacin 500 mg once daily during sequential intravenous/oral therapy in patients with lower respiratory tract infections, J. Antimicrob. Chemother., 51, 101-106 (2003) https://doi.org/10.1093/jac/dkg035
  13. L. Shargel and A.B.C. Yu, Chapter 10. Bioavailability and bioequivalence, In Applied biopharmaceutics and Pharmacokinetics, 3rd ed., p. 193, Appleton & Lange, Nowwalk, USA (1993)